diarrhea in Extend­ed release study [Outliers]

posted by Researcher101 – Egypt, 2020-09-23 19:53 (118 d 03:54 ago) – Posting: # 21935
Views: 361

Dear All, I'm asking if I have a study on product containing two actives (one IR and the other extended release) and a participant had a diarrhea after Tmax of the IR active and through the Tmax of the XR active. should I exclude the participant from the study? or include him in the XR active statistical calculation and exclude in the IR? :confused:

Complete thread:

Activity
 Admin contact
21,306 posts in 4,443 threads, 1,488 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Tuesday 23:48 UTC (Europe/Vienna)

Power: That which is wielded by the priesthood of
clinical trials, the statisticians, and a stick which they use
to beta their colleagues.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5